Linagliptin is an oral antidiabetic pharmaceutical compound belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It is used in the management of type 2 diabetes mellitus by increasing the activity of incretin hormones, which help regulate blood glucose levels. Linagliptin is a selective DPP-4 inhibitor and is used as an active pharmaceutical ingredient in oral antidiabetic formulations.
Linagliptin has the molecular formula C₂₅H₂₈N₈O₂, molecular weight approximately 472.54 g/mol and CAS Number 668270-12-0. Its chemical name is 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione.
Linagliptin is a substituted xanthine-related compound containing a purine-2,6-dione structure, a quinazoline group and an aminopiperidine component. Its defined stereochemistry includes the (3R) configuration. It is generally described as a white to yellowish solid with very low hygroscopicity.
Linagliptin is very slightly soluble in water, soluble in methanol and sparingly soluble in ethanol. These physicochemical properties are important during pharmaceutical formulation development, analytical method selection and quality evaluation.
Linagliptin is used in oral pharmaceutical formulations for improving glycaemic control in adults with type 2 diabetes mellitus, alongside diet and exercise. It works by inhibiting the DPP-4 enzyme, which increases the availability of incretin hormones such as GLP-1 and GIP. These hormones contribute to glucose-dependent insulin secretion and regulation of glucagon release.
Linagliptin is used in the development of tablets, including combination formulations with other antidiabetic ingredients such as Metformin Hydrochloride. Finished tablet specifications, strengths, dissolution and excipient requirements are separate from the bulk API specification.
For this product page, IHS is treated as In-House Specification, rather than a confirmed pharmacopoeial grade. The approved manufacturer specification should define the acceptance limits for assay, organic impurities, enantiomeric purity, water content, residual solvents and other quality parameters.
A USP-NF Linagliptin monograph proposal published in 2026 describes validated analytical procedures for assay, organic impurities and enantiomeric purity. The USP briefing also identifies reference standards for Linagliptin and related compounds. Its proposed analytical methods should not be mistaken for an automatically applicable supplier release specification.
The material should be stored in suitable, tightly closed packaging under the approved manufacturer's storage conditions. The batch COA and current product specification should be reviewed before pharmaceutical use.
1. What is Linagliptin IHS?
Linagliptin IHS refers to Linagliptin supplied against an in-house specification, subject to confirmation from the manufacturer's documentation.
2. What is the CAS number of Linagliptin?
Its CAS Number is 668270-12-0.
3. What is the molecular formula of Linagliptin?
Its molecular formula is C₂₅H₂₈N₈O₂.
4. What is the molecular weight of Linagliptin?
Its molecular weight is approximately 472.54 g/mol.
5. What is the pharmacological category of Linagliptin?
It belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class.
6. What are the pharmaceutical applications of Linagliptin?
It is used in oral antidiabetic formulations for the management of type 2 diabetes mellitus.
7. How does Linagliptin work?
It inhibits the DPP-4 enzyme, helping increase incretin hormone activity and support glucose-dependent insulin secretion.
8. What is the appearance of Linagliptin?
It is generally described as a white to yellowish solid.
9. Is Linagliptin soluble in water?
It is very slightly soluble in water and more soluble in methanol.
10. What does IHS mean in Linagliptin IHS?
In this product-page context, IHS is treated as In-House Specification. The exact meaning should be confirmed from the supplier's grade documentation.
11. Which quality tests are important for Linagliptin?
Important tests may include identification, assay, organic impurities, enantiomeric purity, water content and residual solvents.
12. What documents should be checked before procurement?
Review the approved in-house specification, batch COA, safety data sheet and analytical method documentation.
| Parameter | Specification |
|---|---|
| Appearance | White to yellowish powder |
| Identification | HPLC & IR compliant |
| Assay (HPLC) | 98.0–102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.1% |
| Heavy Metals | NMT 10 ppm |
| Individual Impurity | NMT 0.15% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 5.0% |
| Solubility | very slightly soluble in water |